Correlation between the serum pepsinogen I level and the symptom degree in proton pump inhibitor-users administered with a probiotic

Muneki Igarashi, Jun Nagano, Ayumi Tsuda, Takayoshi Suzuki, Jun Koike, Tetsufumi Uchida, Masashi Matsushima, Tetsuya Mine, Yasuhiro Koga

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In patients with functional upper gastrointestinal disorders such as gastroesophageal reflux disease and functional dyspepsia, the presence of symptoms is thought to occur in the absence of any organic diseases and the mechanisms behind this remain unclear. We therefore examined the relationship between stomach-related biomarker levels and symptoms. Twenty-four outpatients who had taken proton-pump inhibitors every day were enrolled in this study. The subjects consumed yogurt containing 109 colony-forming units of Lactobacillus gasseri OLL2716 (LG21) every day for three months. They underwent four clinical examinations in total. Each examination consisted of answering a questionnaire with a frequency scale for the symptoms of GERD (FSSG), and included measurements of the serum gastrin, ghrelin, and pepsinogens I and II levels. As a result, the FSSG score and the PGI value showed a decrease and an increase, respectively, after LG21 treatment when analyzed without age adjustment. A multiple regression analysis with additional adjustments for gender and age revealed a strong association between the PGI value and the FSSG symptom scores. Therefore either the PGI level itself or the factors regulating the PGI level might be involved in the etiology of these symptoms.

Original languageEnglish
Pages (from-to)754-764
Number of pages11
JournalPharmaceuticals
Volume7
Issue number7
DOIs
Publication statusPublished - Jun 25 2014

Fingerprint

Pepsinogen A
Proton Pump Inhibitors
Probiotics
Gastroesophageal Reflux
Serum
Pepsinogen C
Yogurt
Ghrelin
Gastrointestinal Diseases
Dyspepsia
Stomach
Outpatients
Stem Cells
Biomarkers
Regression Analysis
Lactobacillus gasseri

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Correlation between the serum pepsinogen I level and the symptom degree in proton pump inhibitor-users administered with a probiotic. / Igarashi, Muneki; Nagano, Jun; Tsuda, Ayumi; Suzuki, Takayoshi; Koike, Jun; Uchida, Tetsufumi; Matsushima, Masashi; Mine, Tetsuya; Koga, Yasuhiro.

In: Pharmaceuticals, Vol. 7, No. 7, 25.06.2014, p. 754-764.

Research output: Contribution to journalArticle

Igarashi, M, Nagano, J, Tsuda, A, Suzuki, T, Koike, J, Uchida, T, Matsushima, M, Mine, T & Koga, Y 2014, 'Correlation between the serum pepsinogen I level and the symptom degree in proton pump inhibitor-users administered with a probiotic', Pharmaceuticals, vol. 7, no. 7, pp. 754-764. https://doi.org/10.3390/ph7070754
Igarashi, Muneki ; Nagano, Jun ; Tsuda, Ayumi ; Suzuki, Takayoshi ; Koike, Jun ; Uchida, Tetsufumi ; Matsushima, Masashi ; Mine, Tetsuya ; Koga, Yasuhiro. / Correlation between the serum pepsinogen I level and the symptom degree in proton pump inhibitor-users administered with a probiotic. In: Pharmaceuticals. 2014 ; Vol. 7, No. 7. pp. 754-764.
@article{a0270dd5aa9b40739ef2f8c3588be545,
title = "Correlation between the serum pepsinogen I level and the symptom degree in proton pump inhibitor-users administered with a probiotic",
abstract = "In patients with functional upper gastrointestinal disorders such as gastroesophageal reflux disease and functional dyspepsia, the presence of symptoms is thought to occur in the absence of any organic diseases and the mechanisms behind this remain unclear. We therefore examined the relationship between stomach-related biomarker levels and symptoms. Twenty-four outpatients who had taken proton-pump inhibitors every day were enrolled in this study. The subjects consumed yogurt containing 109 colony-forming units of Lactobacillus gasseri OLL2716 (LG21) every day for three months. They underwent four clinical examinations in total. Each examination consisted of answering a questionnaire with a frequency scale for the symptoms of GERD (FSSG), and included measurements of the serum gastrin, ghrelin, and pepsinogens I and II levels. As a result, the FSSG score and the PGI value showed a decrease and an increase, respectively, after LG21 treatment when analyzed without age adjustment. A multiple regression analysis with additional adjustments for gender and age revealed a strong association between the PGI value and the FSSG symptom scores. Therefore either the PGI level itself or the factors regulating the PGI level might be involved in the etiology of these symptoms.",
author = "Muneki Igarashi and Jun Nagano and Ayumi Tsuda and Takayoshi Suzuki and Jun Koike and Tetsufumi Uchida and Masashi Matsushima and Tetsuya Mine and Yasuhiro Koga",
year = "2014",
month = "6",
day = "25",
doi = "10.3390/ph7070754",
language = "English",
volume = "7",
pages = "754--764",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

TY - JOUR

T1 - Correlation between the serum pepsinogen I level and the symptom degree in proton pump inhibitor-users administered with a probiotic

AU - Igarashi, Muneki

AU - Nagano, Jun

AU - Tsuda, Ayumi

AU - Suzuki, Takayoshi

AU - Koike, Jun

AU - Uchida, Tetsufumi

AU - Matsushima, Masashi

AU - Mine, Tetsuya

AU - Koga, Yasuhiro

PY - 2014/6/25

Y1 - 2014/6/25

N2 - In patients with functional upper gastrointestinal disorders such as gastroesophageal reflux disease and functional dyspepsia, the presence of symptoms is thought to occur in the absence of any organic diseases and the mechanisms behind this remain unclear. We therefore examined the relationship between stomach-related biomarker levels and symptoms. Twenty-four outpatients who had taken proton-pump inhibitors every day were enrolled in this study. The subjects consumed yogurt containing 109 colony-forming units of Lactobacillus gasseri OLL2716 (LG21) every day for three months. They underwent four clinical examinations in total. Each examination consisted of answering a questionnaire with a frequency scale for the symptoms of GERD (FSSG), and included measurements of the serum gastrin, ghrelin, and pepsinogens I and II levels. As a result, the FSSG score and the PGI value showed a decrease and an increase, respectively, after LG21 treatment when analyzed without age adjustment. A multiple regression analysis with additional adjustments for gender and age revealed a strong association between the PGI value and the FSSG symptom scores. Therefore either the PGI level itself or the factors regulating the PGI level might be involved in the etiology of these symptoms.

AB - In patients with functional upper gastrointestinal disorders such as gastroesophageal reflux disease and functional dyspepsia, the presence of symptoms is thought to occur in the absence of any organic diseases and the mechanisms behind this remain unclear. We therefore examined the relationship between stomach-related biomarker levels and symptoms. Twenty-four outpatients who had taken proton-pump inhibitors every day were enrolled in this study. The subjects consumed yogurt containing 109 colony-forming units of Lactobacillus gasseri OLL2716 (LG21) every day for three months. They underwent four clinical examinations in total. Each examination consisted of answering a questionnaire with a frequency scale for the symptoms of GERD (FSSG), and included measurements of the serum gastrin, ghrelin, and pepsinogens I and II levels. As a result, the FSSG score and the PGI value showed a decrease and an increase, respectively, after LG21 treatment when analyzed without age adjustment. A multiple regression analysis with additional adjustments for gender and age revealed a strong association between the PGI value and the FSSG symptom scores. Therefore either the PGI level itself or the factors regulating the PGI level might be involved in the etiology of these symptoms.

UR - http://www.scopus.com/inward/record.url?scp=84903307093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903307093&partnerID=8YFLogxK

U2 - 10.3390/ph7070754

DO - 10.3390/ph7070754

M3 - Article

AN - SCOPUS:84903307093

VL - 7

SP - 754

EP - 764

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 7

ER -